Trials / Unknown
UnknownNCT04370288
Clinical Application of Methylene Blue for Treatment of Covid-19 Patients
The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Mashhad University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The severe acute respiratory syndrome caused by COVID-19 is now a global catastrophic event. Currently there is no approved drug or vaccine for the disease. Methylene blue (MB, oxidized form, blue color) has been used in many different areas of clinical medicine, ranging from malaria to orthopedics. Leucomethylene Blue (reduced form of MB, colorless) may be applied for the treatment of COVID-19 according to the scientific evidences.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MCN (Methylene blue, vitamin C, N-acetyl cysteine) | A mixture of MCN will be injected to covid-19 patients. |
Timeline
- Start date
- 2020-04-19
- Primary completion
- 2020-09-20
- Completion
- 2020-09-21
- First posted
- 2020-04-30
- Last updated
- 2020-05-04
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT04370288. Inclusion in this directory is not an endorsement.